Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Wall Street closed sharply higher on Monday, driven by strong rebounds in major artificial intelligence (AI) and technology ...

Wendy’s plans to close hundreds of US restaurants over the next few months in an effort to boost its profit. The Dublin, Ohio ...

At a price of up to $10 billion, Pfizer has claimed victory in its bidding war against Novo Nordisk to acquire Metsera. It's ...

The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...

Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.